Aubrey de Grey on the TAME Metformin Trial

As you may or may not have heard, the TAME metformin trial recently received the remaining $40 million in philanthropic funding that is needed to progress. The trial will cost $75 million in total, and to my eyes this is quite the waste of funding. Aubrey de Grey of the SENS Research Foundation is far more polite on this topic in today’s editorial, which isn’t too surprising given our respective views on regulation. I’ll set aside for the moment the point that metformin is a weak treatment with a small effect size on life span, unreliable animal data, life span data in humans arising from a single trial for diabetics rather than healthy individuals, and side effects that are significant in comparison to the small effect size

From http://besthealthnews.com/2019/10/aubrey-de-grey-on-the-tame-metformin-trial/?utm_source=rss&utm_medium=rss&utm_campaign=aubrey-de-grey-on-the-tame-metformin-trial

from
https://healthnews010.wordpress.com/2019/10/23/aubrey-de-grey-on-the-tame-metformin-trial-2/

from https://jamesjohnson10.blogspot.com/2019/10/aubrey-de-grey-on-tame-metformin-trial_22.html

from
https://jamesjohnson101.tumblr.com/post/188533013673